Cargando…
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
OBJECTIVE: Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA. We investigated the safety and efficacy of omaveloxol...
Autores principales: | Lynch, David R., Chin, Melanie P., Delatycki, Martin B., Subramony, S. H., Corti, Manuela, Hoyle, J. Chad, Boesch, Sylvia, Nachbauer, Wolfgang, Mariotti, Caterina, Mathews, Katherine D., Giunti, Paola, Wilmot, George, Zesiewicz, Theresa, Perlman, Susan, Goldsberry, Angie, O'Grady, Megan, Meyer, Colin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894504/ https://www.ncbi.nlm.nih.gov/pubmed/33068037 http://dx.doi.org/10.1002/ana.25934 |
Ejemplares similares
-
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
por: Lynch, David R., et al.
Publicado: (2018) -
Longitudinal analysis of contrast acuity in Friedreich ataxia
por: Hamedani, Ali G., et al.
Publicado: (2018) -
Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
por: Ghanekar, Shaila D, et al.
Publicado: (2019) -
Psychometric properties of the Friedreich Ataxia Rating Scale
por: Rummey, Christian, et al.
Publicado: (2019) -
Impact of diabetes in the Friedreich ataxia clinical outcome measures study
por: McCormick, Ashley, et al.
Publicado: (2017)